Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 885

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824

β-Cell Failure in Diabetes and Preservation by Clinical Treatment

WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 722

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 581

Glucagon-like peptide 1 in health and disease

Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528

The incretin system and its role in type 2 diabetes mellitus

Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498

Incretins, insulin secretion and Type 2 diabetes mellitus

Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 456

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414

Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350

Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334

GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study

Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321

The role of gut hormones and the hypothalamus in appetite regulation

Suzuki, K., Simpson, K. A., MINNION, J. S., Shillito, J. C., & Bloom, S. R. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-077 · Cited by 327

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297

Therapeutic Strategies Based on Glucagon-Like Peptide 1

Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

Sonne, D. P., Engstrøm, T., & Treiman, M. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 291

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

Thornberry, N. A., & Gallwitz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.004 · Cited by 285

Recent updates on GLP-1 agonists: Current advancements & challenges

Sharma, D., Verma, S., Vaidya, S. P., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 288

Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 272

Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms

Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2008) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 259

Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake

Dossat, A. M., Lilly, N., Kay, K. E., & Williams, D. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 258

Industrial natural product chemistry for drug discovery and development

Bauer, A., & Brönstrup, M. (2013) · Natural Product Reports · doi:10.1039/c3np70058e · Cited by 262

The incretin system in healthy humans: The role of GIP and GLP-1

Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248

Effects of PYY1–36and PYY3–36on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

Sloth, B., Holst, J. J., Flint, A., Gregersen, N. T., & Astrup, A. V. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00450.2006 · Cited by 250

What do we know about the secretion and degradation of incretin hormones?

Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 244

Small-molecule agonists for the glucagon-like peptide 1 receptor

Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232

Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005

Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228

Semaglutide for the treatment of obesity

Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227

Obesity and Appetite Control

Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/824305 · Cited by 241

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., & Husain, M. (2010) · Endocrinology · doi:10.1210/en.2009-1197 · Cited by 232

Glucagon-Like Peptide 1 Secretion by the L-Cell

Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 220

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206

Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell

Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2008-0726 · Cited by 200

Crystal structure of the GLP-1 receptor bound to a peptide agonist

Jazayeri, A., Rappas, M., Brown, A., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., et al. (2017) · Nature · doi:10.1038/nature22800 · Cited by 204

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 197

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity

Bliss, E., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 196

Battle of GLP-1 delivery technologies

Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 192

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes

Nauck, M. A., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 179

Minireview: Gut Peptides Regulating Satiety

Druce, M. R., Small, C. J., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-0089 · Cited by 177

Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond

Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 178

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 174

Glucagon-like peptide-1, glucose homeostasis and diabetes

Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 162

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 163

Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives

Rekha, M. R., & Sharma, C. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.056 · Cited by 155

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Yoshida, T., Akahoshi, F., Sakashita, H., Kitajima, H., Nakamura, M., Sonda, S., Takeuchi, M., Tanaka, Y., Ueda, N., Sekiguchi, S., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.012 · Cited by 159

Neuroprotective properties of GLP-1: theoretical and practical applications

Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 154

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 149

The effect of glucagon-like peptide 1 on cardiovascular risk

Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

Neumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 144

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142

Targeting the glucagon receptor family for diabetes and obesity therapy

Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs

Simonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133

One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer

Luginbuhl, K. M., Schaal, J. L., Umstead, B. R., Mastria, E. M., Li, X., Banskota, S., Arnold, S. E., Feinglos, M. N., D’Alessio, D. A., & Chilkoti, A. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0078 · Cited by 129

Physiology of Incretins in Health and Disease

Deacon, C. F., & Åhrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 135

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125

Incretins: their physiology and application in the treatment of diabetes mellitus

Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121

Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin

Uchida, M., Ohshiba, Y., & Mogami, O. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11089sc · Cited by 119

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 120

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 120

Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes

Deacon, C. F., & Holst, J. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.011 · Cited by 117

The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review

Aroda, V. R., & Ratner, R. E. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1202 · Cited by 112

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 112

The Glucagon‐Like Peptides

Brubaker, P. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.006 · Cited by 118

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Konrad, R. J., Sloan, J. H., Drent, M. L., Diamant, M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3754-x · Cited by 108

G protein-coupled receptors as targets for anti-diabetic therapeutics

Oh, D. Y., & Olefsky, J. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.4 · Cited by 110

The modulatory role of high fat feeding on gastrointestinal signals in obesity

Duca, F. A., Sakar, Y., & Covașă, M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.05.005 · Cited by 112

Long-acting parenteral drug delivery systems for the treatment of chronic diseases

Jindal, A. B., Bhide, A. R., Salave, S., Rana, D., & Benival, D. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114862 · Cited by 111

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

Cai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108

Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment

Schiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 110

The Incretin Approach for Diabetes Treatment

Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 110

Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

Patel, B., & Ghate, M. D. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.038 · Cited by 107

GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways

Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104

Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

Tran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed Central · Cited by 102

Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter

Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 108

Targeting the incretin system in obesity and type 2 diabetes mellitus

Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 110

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/eoed.9.1.155.32952 · Cited by 104

Protein Kinase Cζ Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells

Iakoubov, R., Izzo, A. A., Yeung, A., Whiteside, C. I., & Brubaker, P. L. (2006) · Endocrinology · doi:10.1210/en.2006-1403 · Cited by 103

Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is required for food intake control

Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102

Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus

Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 103

GLP-1 and Exendin-4 Transiently Enhance GABAA Receptor–Mediated Synaptic and Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons

Korol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2015) · Diabetes · doi:10.2337/db14-0668 · Cited by 101

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99

Liraglutide: the therapeutic promise from animal models

Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 102

Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial

Lertrit, A., Srimachai, S., Saetung, S., Chanprasertyothin, S., Chailurkit, L., Areevut, C., Katekao, P., Ongphiphadhanakul, B., & Sriphrapradang, C. (2018) · Nutrition · doi:10.1016/j.nut.2018.04.001 · Cited by 95

Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study

Gaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95

Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus

Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95

Effects of GLP-1 in the Kidney

Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 95

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo

Dong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93

Incretins in obesity and diabetes

Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93

Glucose-dependent insulinotropic polypeptide (GIP)

Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 103

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Jimenez‐Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010) · PubMed · Cited by 89

Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia?

Hansen, A. M., Bodvarsdottir, T. B., Nordestgaard, D. N. E., Heller, R., Gotfredsen, C., Maedler, K., Fels, J., Holst, J. J., & Karlsen, A. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2080-1 · Cited by 93

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

Deane, A. M., Chapman, M. J., Fraser, R. J., Burgstad, C. M., Besanko, L. K., & Horowitz, M. (2009) · Critical Care · doi:10.1186/cc7874 · Cited by 89

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75

Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251

Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes

Gutniak, M., Svartberg, J. B., Hellström, P. M., Holst, J. J., Adner, N., & Åhrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369